{"id":"W2006813505","doi":"10.1097/jto.0b013e3181cee24f","title":"Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Neutropenia; Internal medicine; Interim analysis; Lung cancer; Febrile neutropenia; Phases of clinical research; Discontinuation; Adverse effect; Leukopenia; Combination therapy; Oncology; Surgery; Chemotherapy; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001754046,0.002511561,0.004836467,0.0005062915,0.0005894402,0.001342727,0.001460901,0.001957171,0.007629073],"category_scores_gemma":[0.001698088,0.001143517,0.001533942,0.0004755165,0.001614314,0.001506841,0.0004840193,0.004310067,0.001403405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001045718,"about_ca_system_score_gemma":0.001929437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00139815,"about_ca_topic_score_gemma":0.002780536,"domain_scores_codex":[0.9993895,0.0003059266,0.00002841796,0.0001243122,0.00003937384,0.0001124103],"domain_scores_gemma":[0.998916,0.0002852205,0.0001648148,0.00011781,0.00006777929,0.0004483611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.973906,0.01352884,0.0002341981,0.0002479858,0.0004310831,0.00002086952,0.00004273988,0.0004278317,0.002212067,0.0001045386,0.0005281667,0.008315673],"study_design_scores_gemma":[0.9504346,0.04804016,0.0004900762,0.000007882515,0.000124328,0.00001362138,0.00001286415,0.000309508,0.0002202691,0.00008207662,0.0002559327,0.000008656341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849502,0.002335115,0.00138145,0.0008568761,0.0008849202,0.005878907,0.001187177,0.0001973144,0.002328051],"genre_scores_gemma":[0.9782917,0.002157303,0.002734988,0.001406251,0.0005400416,0.00763168,0.00117475,0.00005637198,0.006006858],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007629073,"threshold_uncertainty_score":0.02552176,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01931952276441427,"score_gpt":0.4345778015929574,"score_spread":0.4152582788285432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}